



# Bulletin from Annual General Meeting in IRRAS on April 28, 2021

The Annual General Meeting (the "AGM") on April 28, 2021 resolved to adopt the balance sheet, income statement, consolidated income statement and consolidated balance sheet for 2020. Furthermore, it was resolved that no dividend will be distributed and disposable profits as of December 31, 2020 are carried forward.

The AGM also resolved to discharge the board members and the CEO from liability for 2020.

The AGM approved the nominating committee's proposal that the board shall consist of five board members. The AGM resolved that the total board remuneration shall amount to SEK 1,786,000 of which SEK 540,000 shall be paid to the Chairman of the Board of Directors and SEK 265,000 shall be paid to each of the other board members elected by the General Meeting and who are not employees of the group. Board members who are residents in the United States shall be paid an additional amount of SEK 106,000. For work in the Audit Committee, the remuneration to the Chairman of the Committee amounts to SEK 130,000 and SEK 65,000 to the other member of the Committee. For work in the Remuneration Committee, the remuneration to the Chairman of the Committee amounts to SEK 100,000 and SEK 50,000 to the other member of the Committee. No extra compensation will be paid for participating in other committees. The total remuneration on a total of SEK 1,786,000 as stated above requires that the Audit Committee consists of two members and that the Remuneration Committee consists of two members. The AGM also resolved that the remuneration to the auditor, as previous, shall be paid in accordance with approved invoices.

The AGM resolved that the board until the end of the next AGM meeting will consist of the members Kleanthis G. Xanthopoulos, Marios Fotiadis, Anita Tollstadius, Eva Nilsagård and Catherine Gilmore-Lawless. Marios Fotiadis was elected chairman of the board. KPMG AB was re-elected as the company's auditor, with Duane Swanson as auditor in charge, until the end of the AGM of 2022.

The AGM approved the board's report on remunerations.

The AGM approved the board's proposal regarding a long-term incentive program 2021 (LTIP 2021) in accordance with items A and B of the proposal.

The AGM approved the board's proposal to be authorized to increase share capital through the issue of new shares, warrants and/or convertibles.

Complete proposals regarding the AGM's decisions are available on IRRAS AB's website [www.iras.com](http://www.iras.com).

## About IRRAS

IRRAS is a global medical care company focused on innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRASflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit [www.irras.com](http://www.irras.com).

IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker: IRRAS).

**For more information, please contact:**

**USA**

Kleanthis G. Xanthopoulos, Ph.D.

CEO

[ir@irras.com](mailto:ir@irras.com)

**Europe**

Sabina Berlin

CFO

+46 73 951 95 02

[sabina.berlin@irras.com](mailto:sabina.berlin@irras.com)

*The information was released for public disclosure, through the agency of the contact persons above, on April 28, 2021 at 19:30 (CET).*